Abstract
Objective To study the biodistribution of 18F-Alfatide in lung cancer patients. Methods Fifteen patients (12 males, 3 females, average age: (56±9) years) with suspicious lung cancer underwent PET/CT imaging. Images were acquired for each patient 60 min after injection of 18F-Alfatide (3.7 MBq/kg), covering a field of view from the thigh to the skull. SUVmax and SUVmean were calculated with ROI method. Immunohistochemistry test of tumor samples was performed to confirm the expression of integrin αvβ3. The relationship between the accumulation of 18F-Alfatide and the expression of αvβ3 was analyzed by Spearson rank correlation. Results There were 7 patients with squamous cell carcinoma, 7 patients with adenocarcinoma and 1 patient with small cell lung cancer. 18F-Alfatide was excreted by the kidneys. The radioactivity was quickly eliminated from plasma. The high accumulation of radioactivity was found in the liver, spleen and kidneys. 18F-Alfatide PET imaging identified all tumors. The SUVmax and SUVmean of tumors were 4.27±1.32 and 2.75±0.77 respectively. T/NT ratio was 15.19±9.33. The uptake of 18F-Alfatide in tumor tissues correlated with the expression level of integrin αvβ3 (rs=0.765, P<0.05). Conclusion 18F-Alfatide has a favorable property of tissue biodistribution and can be effectively used for αvβ3-positive tumor imaging. Key words: Lung neoplasms; Peptides, cyclic; Arg-Gly-Asp; Fluorine radioisotopes; Tomography, emission-computed; Tomography, X-ray computed
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
